Solid Biosciences

Don’t miss a free community webinar we are co-hosting with @defeatduchenne on Wednesday, May 27, at 1:00 PM ET. We look forward to discussing SGT-003, our investigational gene therapy for #DuchenneMuscularDystrophy, and our two ongoing Duchenne clinical trials. Tune in as Annie Ganot and Patrick Gonzalez, PhD, discuss program progress and answer questions from the Duchenne community. #GeneTherapy #DuchenneCommunity

Solid Biosciences today announced financial results and business updates for the first quarter of 2026. Read the full release: investors.solidbio.com/news-releases/… $SLDB

Solid Biosciences is pleased to announce that the first participant has been dosed in the Phase 3 IMPACT DUCHENNE trial evaluating SGT-003, our investigational gene therapy for Duchenne muscular dystrophy. As we advance this clinical program, we recognize that milestones like this are only achieved through collaboration. Thank you to the patients, families, and investigators who are making this work possible as we strive to drive meaningful change for the #Duchenne community. investors.solidbio.com/news-releases/… #GeneTherapy #DuchenneMuscularDystrophy #DuchenneCommunity

Solid Biosciences’ Chief Medical Officer, Gabriel Brooks, M.D., will be presenting at #FierceBiotechWeek on Wednesday, May 13, from 10:10 - 10:35 am in Boston, MA. He will discuss a critical challenge in genetic medicine: ensuring therapies are delivered precisely where they are needed most. Learn more about the session here: fiercebiotechweek.com/event/fierce-b… #GeneTherapy #GeneticMedicine #SolidInside

In recognition of Friedreich’s Ataxia Awareness Month, we stand alongside the FA community and reaffirm our commitment to advancing research together. To ensure our work remains rooted in real-world experiences, we recently hosted an internal panel discussion focused on the realities of living with FA at our headquarters in Boston. We are incredibly grateful for the opportunity to learn directly from patients, families, and healthcare professionals. Listening to your voices is essential to help us both deepen our understanding of unmet needs and guide our work forward. A big thank you to our panelists: @RussellLonser, Marinda Cauley, and Liam Cauley #CommunityToCureFA #FriedreichAtaxia #RareDisease #PatientAdvocacy

We are excited to head to #ASGCT2026, where Solid will deliver our largest number of presentations at a single scientific meeting. Alongside our multiple oral and poster presentations, Armatus Bio will be presenting a poster highlighting the potential of POLARIS-101™ in Facioscapulohumeral muscular dystrophy (FSHD). ASGCT provides an important forum to highlight the breadth and depth of our science, and we look forward to engaging with the broader gene and cell therapy community. Read the full release to learn more: investors.solidbio.com/news-releases/… #SolidInside #ASGCT #GeneAndCellTherapy #PrecisionGeneticMedicine #RareDisease

We are pleased to announce that the European Commission has granted Orphan drug designation to SGT-003 for the treatment of Duchenne muscular dystrophy. The designation underscores Solid’s commitment to advance SGT-003 through a global development effort for individuals living with this condition. Read the full release: investors.solidbio.com/news-releases/… #Duchenne #DuchenneMuscularDystrophy #GeneTherapy

We’re honored to have attended and sponsored @SADSFoundation’s Challenging Cases in Inherited Arrhythmias Symposium and Reception last week. Our team was on the ground to support the foundation in its important research and awareness surrounding genetic heart rhythm conditions and share details about our investigational gene therapy, SGT-501, for treating catecholaminergic polymorphic ventricular tachycardia (#CPVT). #GeneTherapy

We are looking forward to participating in the upcoming @TeamJosephInfo Stronger Together meeting next week. True progress takes a village, and we appreciate the opportunity to sit down with other industry partners and Duchenne advocates to discuss how our community can continue driving critical advancements forward. Learn more about the important work Team Joseph is doing at teamjoseph.org. #TeamWork #StrongerTogether #Community #TeamJoseph #Caregivers #DMD #DuchenneMuscularDystrophy

#PRESS “[SGT-212 is] one of the first gene therapies for Friedreich's ataxia to enter human trials, and the first that is designed to address both neuromuscular and cardiac manifestations of the disease using a novel dual administration route… ‘We need to bring the medicine to the organs affected — the heart and the brain,’ specifically the cerebellar dentate nucleus, [Dr. Gabriel Brooks] said.” Solid Biosciences is thrilled to advance its first-in-human trial of SGT-212, an investigational gene therapy for Friedreich’s ataxia, a rare, inherited disorder with devastating and degenerative impact on neuromuscular and cardiac function. Read the full story to learn more about SGT-212 and the Phase 1b FALCON clinical trial. precisionmedicineonline.com/Reprint-GW2600… #FriedreichsAtaxia #RareDisease #GeneTherapy #ClinicalTrials

Solid Biosciences’ Medical Director and Therapeutic Head, Neuromuscular, Matthew Harmelink, will be presenting at the upcoming @CureFA_org (FARA) research reception. We’ll be joining the #FriedreichsAtaxia community on the ground in California to discuss Solid's Phase 1b FALCON clinical trial evaluating SGT-212, our novel, dual-route administration investigational gene therapy for FA.

Solid Biosciences will be at @OSUGeneTherapy & @nationwidekids' 2nd Annual Gene Therapy Symposium this week presenting on the exciting advancements of precision targeting in #GeneTherapy. Joining live? Check out our Chief Medical Officer, Gabriel Brooks', presentation: Next-Generation Precision Targeting in Gene Therapy Next Generation AAV Capsids - Breakout Session 2: 3rd floor, Pheoris West

Solid is thrilled to be a supporting sponsor at @NAF_Ataxia's Annual Ataxia Conference taking place this weekend in Orlando, Florida. We are pleased to make meaningful connections with patients and families in the ataxia community and share information about our Phase 1b FALCON trial for SGT-212, our investigational gene therapy for Friedreich's ataxia. Stop by the Solid exhibit table to connect! #FriedreichsAtaxia

Our President and CEO, Bo Cumbo will be participating in a virtual fireside chat at the 25th Annual Needham Virtual Healthcare Conference on Tuesday, April 14, 2026, at 2:15 pm ET. Catch the webcast at: investors.solidbio.com/news-and-event…. The Solid team will also be attending the Piper Sandler Spring Biopharma Symposium in Boston on April 16th where members of the management will participate in 1x1 investor meetings. Reach out to your conference representative to schedule a meeting. #SolidBiosciences

The Solid team had a great time at @loonmtn hitting the slopes with @NEDisabledSport (NEDS)! 🏂❄️ Helping athletes experience the joy of adaptive sports never gets old and we’re grateful to have had the opportunity to join NEDS and the #Duchenne community once again for this incredible event. #TeamSolid #AdaptiveSports #DuchenneCommunity

Solid Biosciences today announced our financial results for the fourth quarter and full year 2025, along with business and pipeline updates. Read the full release: investors.solidbio.com/news-releases/… #SolidBiosciences $SLDB